Abstract
Killing properties of antitumor drugs can be enhanced by strategies targeting biochemical adaptations of cancer cells. Recently, we reported that depriving cancer cells of glutamine is a feasible approach to enhance antitumor effects of the alkylating analog of pyruvic acid, 3-bromopyruvate, which rely on the induction of autophagic cell death by metabolic-oxidative stress. 3-bromopyruvate chemopotentiation is the result of its increased intracellular uptake mediated by the monocarboxylate transporter 1, whose expression is post-transcriptionally increased upon glutamine withdrawal. Overall, our results identified the metabolic condition able to increase the selectivity of 3-bromopyruvate targets in neoplastic tissues, thereby providing a stage for its use in clinical settings for targeting malignancies and represent a proof of principle that modulation of glutamine availability can influence the delivery of monocarboxylic drugs into tumors.
Original language | English |
---|---|
Pages (from-to) | 1830-1832 |
Number of pages | 3 |
Journal | Autophagy |
Volume | 8 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2012 |
Keywords
- 3-Bromopyruvate
- Chemopotentiation
- Glutamine deprivation
- MCT-1
- Metabolic oxidative stress
ASJC Scopus subject areas
- Cell Biology
- Molecular Biology